136 related articles for article (PubMed ID: 1283750)
1. Octreotide in the management of inoperable gastrointestinal obstruction in terminal cancer patients.
Mercadante S; Maddaloni S
J Pain Symptom Manage; 1992 Nov; 7(8):496-8. PubMed ID: 1283750
[No Abstract] [Full Text] [Related]
2. The palliative effects of octreotide in malignant disease.
Dean A; Bridge D; Lickiss JN
Ann Acad Med Singap; 1994 Mar; 23(2):212-5. PubMed ID: 7521613
[TBL] [Abstract][Full Text] [Related]
3. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial.
Mystakidou K; Tsilika E; Kalaidopoulou O; Chondros K; Georgaki S; Papadimitriou L
Anticancer Res; 2002; 22(2B):1187-92. PubMed ID: 12168923
[TBL] [Abstract][Full Text] [Related]
4. Palliation of malignant intestinal obstruction using octreotide.
Khoo D; Hall E; Motson R; Riley J; Denman K; Waxman J
Eur J Cancer; 1994; 30A(1):28-30. PubMed ID: 7511400
[TBL] [Abstract][Full Text] [Related]
5. Octreotide for malignant bowel obstruction: twenty years after.
Mercadante S; Porzio G
Crit Rev Oncol Hematol; 2012 Sep; 83(3):388-92. PubMed ID: 22277783
[TBL] [Abstract][Full Text] [Related]
6. Comparison of octreotide and hyoscine butylbromide in controlling gastrointestinal symptoms due to malignant inoperable bowel obstruction.
Mercadante S; Ripamonti C; Casuccio A; Zecca E; Groff L
Support Care Cancer; 2000 May; 8(3):188-91. PubMed ID: 10789958
[TBL] [Abstract][Full Text] [Related]
7. The role of octreotide in malignant bowel obstruction.
Krammer LM
Oncol Nurs Forum; 1999 Jun; 26(5):831-2. PubMed ID: 10382174
[No Abstract] [Full Text] [Related]
8. The use of octreotide in bowel obstruction.
Mercadante S
Palliat Med; 1993; 7(1):78. PubMed ID: 8287204
[No Abstract] [Full Text] [Related]
9. Octreotide in the management of bowel obstruction in terminal ovarian cancer.
Mangili G; Franchi M; Mariani A; Zanaboni F; Rabaiotti E; Frigerio L; Bolis PF; Ferrari A
Gynecol Oncol; 1996 Jun; 61(3):345-8. PubMed ID: 8641613
[TBL] [Abstract][Full Text] [Related]
10. Octreotide prevents the pathological alterations of bowel obstruction in cancer patients.
Mercadante S; Avola G; Maddaloni S; Salamone G; Aragona F; Rodolico V
Support Care Cancer; 1996 Sep; 4(5):393-4. PubMed ID: 8883235
[No Abstract] [Full Text] [Related]
11. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
Hisanaga T; Shinjo T; Morita T; Nakajima N; Ikenaga M; Tanimizu M; Kizawa Y; Maeno T; Shima Y; Hyodo I
Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
[TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
Uchino R; Kusano S; Hanada N; Ohara C; Okino T; Yamaguchi K
Gan To Kagaku Ryoho; 2011 Feb; 38(2):255-7. PubMed ID: 21368489
[TBL] [Abstract][Full Text] [Related]
13. Octreotide prescribing patterns in the palliation of symptomatic inoperable malignant bowel obstruction patients at a single US academic hospital.
Hwang M; Pirrello R; Pu M; Messer K; Roeland E
Support Care Cancer; 2013 Oct; 21(10):2817-24. PubMed ID: 23732621
[TBL] [Abstract][Full Text] [Related]
14. Octreotide in malignant intestinal obstruction.
Pandha HS; Waxman J
Anticancer Drugs; 1996 Jan; 7 Suppl 1():5-10. PubMed ID: 8822079
[TBL] [Abstract][Full Text] [Related]
15. Clinical impact of palliative treatment using octreotide for inoperable malignant bowel obstruction caused by advanced urological cancer.
Kubota H; Taguchi K; Kobayashi D; Naruyama H; Hirose M; Fukuta K; Kubota Y; Yasui T; Yamada Y; Kohri K
Asian Pac J Cancer Prev; 2013; 14(12):7107-10. PubMed ID: 24460259
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in patients with inoperable malignant bowel obstruction: secondary outcome from a double-blind, parallel, placebo-controlled randomised trial of octreotide.
McCaffrey N; Asser T; Fazekas B; Muircroft W; Agar M; Clark K; Eckermann S; Lee J; Joshi R; Allcroft P; Sheehan C; Currow DC
BMC Cancer; 2020 Oct; 20(1):1050. PubMed ID: 33129304
[TBL] [Abstract][Full Text] [Related]
17. Antisecretory agents in gastrointestinal obstruction.
Muir JC; von Gunten CF
Clin Geriatr Med; 2000 May; 16(2):327-34. PubMed ID: 10783431
[TBL] [Abstract][Full Text] [Related]
18. A prospective study on the efficacy of octreotide in the management of malignant bowel obstruction in gynecologic cancer.
Watari H; Hosaka M; Wakui Y; Nomura E; Hareyama H; Tanuma F; Hattori R; Azuma M; Kato H; Takeda N; Ariga S; Sakuragi N
Int J Gynecol Cancer; 2012 May; 22(4):692-6. PubMed ID: 22343971
[TBL] [Abstract][Full Text] [Related]
19. [Effective made of octreotide intravenous administration for malignant gastrointestinal obstruction in terminal cancer patients].
Tanimura K; Onda S; Mitsunobu M
Gan To Kagaku Ryoho; 2010 Oct; 37(10):1991-3. PubMed ID: 20948271
[TBL] [Abstract][Full Text] [Related]
20. Practice Patterns of Medications for Patients With Malignant Bowel Obstruction Using a Nationwide Claims Database and the Association Between Treatment Outcomes and Concomitant Use of H
Minoura T; Takeuchi M; Morita T; Kawakami K
J Pain Symptom Manage; 2018 Feb; 55(2):413-419.e2. PubMed ID: 29122616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
